Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gregory Hogle

Plastic Surgery within the Head & Neck Denver, CO Doctor of Osteopathy

NPI 1689669970 CMS profile 411301

4600 Hale Pkwy, Ste 450, Denver, CO 80220

Open in the dashboard

General payments

$768

16 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gregory Hogle of Denver, CO is reported in the CMS Open Payments database as having received $768 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Plastic Surgery within the Head & Neck profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $86 3
2023 General $210 3
2021 General $161 4
2020 General $68 3
2019 General $242 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Hogle
  • Plastic Surgery within the Head & Neck median
  • Middle half of Plastic Surgery within the Head & Neck
  • National median

In program year 2025, general payments to Gregory Hogle were reported at $0. Among 399 Plastic Surgery within the Head & Neck profiles paid that year, the median was $237 and the middle half received between $103 and $520.

Show as a table
Year Gregory Hogle Plastic Surgery within the Head & Neck median Middle half National median
2019 $242 $200 $82–$550 $163
2020 $68 $120 $46–$330 $114
2021 $161 $166 $60–$382 $132
2022 $0 $208 $83–$530 $149
2023 $210 $202 $77–$538 $160
2024 $86 $260 $99–$645 $164
2025 $0 $237 $103–$520 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Stryker Corporation $409 9 payments
  2. Acclarent, Inc $171 1 payment
  3. Integra LifeSciences Corporation $67 2 payments
  4. Medtronic USA, Inc. $63 1 payment
  5. Merck Sharp & Dohme Corporation $20 1 payment
  6. Hikma Pharmaceuticals USA $20 1 payment
  7. Genzyme Corporation $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $768 16 payments
Products named General payments · program years 2019–2024
  1. ENTELLUS - XPRESS ENT DILATION SYSTEM $192 2 payments
  2. Relieva Spinplus $171 1 payment
  3. SCOPIS ENT $125 2 payments
  4. Integra Recon-Skin And Wound $67 2 payments
  5. Integra Recon-Skin And Wound $67 2 payments
  6. Integra Recon-Skin And Wound $67 2 payments
  7. INTEGRA DERMAL REGENERATION TEMPLATE $67 2 payments
  8. PRIMATRIX $67 2 payments
  9. NAVIGUS $63 1 payment
  10. ENTELLUS - XEROGEL NASAL/EPISTAXIS PACK $27 1 payment
  11. Other $104 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,095

Median for Otolaryngology: 297

Drug cost

$25,434

Median for Otolaryngology: $6,314

Branded share of claims

18.8%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Neomycin-Polymyxin-Hc Neomycin/Polymyxin B/Hydrocort Brand 52 $2,819
Valacyclovir Valacyclovir Hcl Brand 35 $2,745
Azelastine Hcl Generic 67 $2,255
Clarithromycin Generic 58 $2,166
Fluticasone Propionate Generic 125 $2,076
Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth Brand 14 $1,707
Omeprazole Generic 101 $1,609
Clotrimazole Generic 70 $1,483
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 65 $1,120
Nortriptyline Hcl Generic 64 $798

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$32,878

Medicare's payments for the services billed

Medicare patients

149

Average age 75

Services billed

356

89 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 53%
Depression 30%
Ischemic heart disease 26%
Chronic kidney disease 18%
Diabetes 17%
Osteoporosis 17%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery within the Head & Neck in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record